Pfizer, Inc. · NYSE:PFE
Pfizer — Investor Day (July 2008)
49 slides from Pfizer's investor day presentation, Jul 28, 2008
Slide 1: Advancing Neuroscience
Advancing Neuroscience Analyst & Investor Briefing July 28, 2008 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information ` Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in P
Slide 3: Agenda
Agenda ` An Introduction to Pfizer’s Neuroscience Portfolio ` Pfizer’s Evolving Vision for In-line Products ` Alpha-2 Delta Platform ` “Invest to Win” Disease Areas Alzheimer’s disease Schizophrenia / Bipolar Disorder ` Recap & Future Outlook 3
Slide 4: An Introduction to Pfizer's Neuroscience Portfolio
An Introduction to Pfizer’s Neuroscience Portfolio Steve Romano, MD Vice President, Global Medical 4
Slide 5: Neuroscience Leadership
Neuroscience Leadership Market Potential Pfizer Success Factors ` Strong track record + ` Significant unmet needs in neuroscience ` Large market opportunities ` Near-term growth ` Limited approved therapeutic ` Valuable in-line portfolio approaches ` Well-positioned to capitalize on emerging science
Slide 6: Pfizer Therapeutic Area Priorities
Pfizer Therapeutic Area Priorities Invest Invest to to Win Win First or High Market High Best in Class Growth Unmet Need 9 9 9 ` Alzheimer’s disease ` Schizophrenia / Bipolar Disorder ` Pain ` Diabetes/Obesity ` Immunology/Inflammation ` Oncology 6
Slide 7: Pfizer Neuroscience Pipeline Overview
Pfizer Neuroscience Pipeline Overview Platform Key Alzheimer’s Schizophrenia; Bipolar disorder 9 compounds Alpha-2-delta for Schizophrenia, Bipolar disorder and Other cognition Geodon for RAGE Inhibitor Adjunctive Use in Bipolar Depression LYRICA 6 compounds PDE 10-A Inhibitor for AD Geodon for Bipo
Slide 8: An Evolving Vision for In-line Products
An Evolving Vision for In-line Products 8
Slide 9: CHANTIX: Scope of the Worldwide Smoking Epidemic
CHANTIX: Scope of the Worldwide Smoking Epidemic 1.3 Billion Smokers Canada Europe Region 5M 215M Japan U.S. 30M 45M China India >300M >100M Brazil 18M Source: 2008 WHO Estimates 9
Slide 10: CHANTIX: For Smokers Motivated to Quit
CHANTIX: For Smokers Motivated to Quit 45M Smokers 30M Smokers in the U.S. Motivated to Quit Control Immature Takers Quitters 29% 12% 13.0M Desire to Quit Chantix Target MD/Rx- Defiant Dependent Smokers Quitters 22% 37% 16.7M Openness to Medical Intervention 10
Slide 11: CHANTIX: Develop the Smoking Cessation Market to Drive Growth
CHANTIX: Develop the Smoking Cessation Market to Drive Growth Consumer Professional ` Communicate the full efficacy/ safety profile of Chantix ` Educate doctors on the difficulties patients face when quitting smoking Access & Reimbursement ` Recently launched unbranded ad campaign designed to ` Driv
Slide 12: GEODON: Continues to Generate Growth
GEODON: Continues to Generate Growth Quarterly Sales ($ M) ` U.S. Geodon field force realigned to focus on specialists 300 across treatment settings 250 ` FY 2007 U.S. sales up 11% to $702 million vs. 2006 200 150 ` Total 1H08 sales of $473 million 100 50 0 6 6 6 6 7 7 7 7 8 8 10 20 30 40 10 20 30 4
Slide 13: GEODON: Pfizer Is Committed to Further Clinical Development
GEODON: Pfizer Is Committed to Further Clinical Development BIPOLAR DISORDER PHASE 3 STUDIES ` Monotherapy studies in Bipolar Depression: Completing ` Adjunctive use in Bipolar Depression: Study initiated in 2008 ` Bipolar Relapse Prevention: Ongoing PEDIATRIC EXCLUSIVITY ` Bipolar Mania: Completed
Slide 14: ARICEPT Continues To Grow And Lead
ARICEPT Continues To Grow And Lead Global Alzheimer’s (AD) Market Total WW MAT*/4/08 Sales Share AD MARKET $6.0 B 100% $7.0 ARICEPT $3.2 B 54% OTHER $2.8 B 46% $6.0 $5.0 $ Billions $4.0 $3.0 $2.0 $1.0 $0.0 4/04 7/04 10/04 1/05 4/05 7/05 10/05 1/06 4/06 7/06 10/06 1/07 4/07 7/07 10/07 1/08 4/08 *Roll
Slide 15: ARICEPT: Major Initiatives Around Early AD Dx and Persistency
ARICEPT: Major Initiatives Underway Around Early AD Dx and Persistency Mild AD Sufferers Globally Continuing Patients in US Largely Undiagnosed and Untreated Represent Bulk of RX Mild 88% of 72% Patients Moderate 22% Persistent With Rx 6% 7% New Severe 5% Other In US, Germany, France, Italy, Spain,
Slide 16: ARICEPT: New U.S. Ad Campaigns Aim to Improve Diagnosis, Treatment, Persistence
ARICEPT: New U.S. Ad Campaigns Aim to Improve Diagnosis, Treatment, Persistence Unbranded DRTV Branded DTC Launched Feb 2008 Launched June 2008 16
Slide 17: LYRICA: A Young, Strong and Growing Brand
LYRICA: A Young, Strong and Growing Brand ` 2007 sales totaled $1.8B, +58% Y/Y Quarterly Sales ($ M) ` Strong global TRx growth 700 Global growth driven by NeP and 600 US Fibromyalgia strong U.S. fibromyalgia launch Approval performance 500 ` Leadership in neuropathic pain 400 Market leader in D
Slide 18: LYRICA Lifecycle Plan: Strengthen Core Indications and Expand
LYRICA Lifecycle Plan: Strengthen Core Indications and Expand 2007 2009+ Core Indications Planned Indications Traditional NeP Traditional NeP • PHN/ DPN Epilepsy • PHN/DPN • Adjunct • Additional indications GAD (EU) Epilepsy Post-Op • Mono Pain Fibro • Pediatric (US) Fibromyalgia (+EU) RLS GAD (+US)
Slide 19: Alpha-2-Delta (a2d) Platform
Alpha-2-Delta (a2d) Platform 19
Slide 20: D2G Mechanism of Action
D2G Mechanism of Action *Does not greatly alter Ca++ influx in normal neurons 20
Slide 21: PD-332,334 May Offer a Unique Value Proposition in GAD
PD-332,334 May Offer a Unique Value Proposition in GAD Fast Sustained Somatic Psychic No Sexual Low Abuse Sleep Onset Effect Symptoms Symptoms Dysfunction Potential Benefits PD-332,334 Benzos +/- SSRI/ SNRIs +/- 21
Slide 22: PD-200,390 a2d for Insomnia in Phase II Studies
PD-200,390 a2d for Insomnia Including Non-restorative Sleep in Phase II Studies Core Components of Insomnia ` Can occur alone Difficulty Difficulty or in combination Initiating Maintaining ` NRS occurring independent Sleep Sleep of DIS or DMS can lead to (DMS) significant daytime functional (DIS) im
Slide 23: NRS Methodology Study (presented at APSS June 2008)
NRS Methodology Study (presented at APSS June 2008) ` Study validated a population with NRS in the absence of DIS or DMS, by objective PSG assessment ` NRS-only subjects’ PSG-measured sleep parameters matched those of healthy control subjects, but this group exhibited daytime functional impairment s
Slide 24: D2G In Neuroscience Summary
D2G In Neuroscience Summary ` Pfizer continues to lead innovation with alpha-2-deltas ` PD-332,334 may offer improved treatment for GAD ` PD-200,390 offers unique potential to treat NRS, a key component of insomnia 24
Slide 25: Investing to Win in Alzheimer's Disease
Investing to Win in Alzheimer’s Disease Liam Ratcliffe, MD, PhD Senior Vice President and Development Head for Pfizer Neuroscience 25
Slide 26: Alzheimer's is a Large and Growing Market
Alzheimer’s is a Large and Growing Market Epidemiology, Diagnosis and ` By 2020… Treated Rates for the Major Markets An aging population will Prevalence, Dx, and Tx Prevalence in 7 Major result in a ~30% increase Growth in 7 Major Markets Markets and China in prevalence 12.5M 27.1M Improved tool
Slide 27: Investment In Diagnostics Presents Further Commercial Opportunities in AD
Investment In Diagnostics Presents Further Commercial Opportunities in AD Emerging screening and diagnostic tools will allow for earlier treatment of the prodromal population Biochemical Markers Imaging Currently Diagnosed and Treated Patients Currently Undiagnosed Patients Prodromal Mild Mod. Sever
Slide 28: New Theories of AD Mechanisms Driving Current Research
New Theories of AD Mechanisms Driving Current Research Aβ Antibodies and RAGE Antagonists Secretase Inhibitors Increase clearance of AE decrease Amyloid Plaque Block production of AE, decreasing buildup in the brain and reduce inflammation Amyloid Plaque buildup in the brain Tau Kinase Inhibitors PD
Slide 29: Pfizer Leading the Industry in Studying RAGE
Pfizer Leading the Industry in Studying RAGE Pfizer is the only company studying RAGE in the clinic; currently in Phase 2 29
Slide 30: Two RAGE Studies Being Presented at ICAD
Two RAGE Studies Being Presented at ICAD Pre-clinical Data Phase 2 Study Schematic 30
Slide 31: Larger Phase 2 RAGE Study Now Underway
Larger Phase 2 RAGE Study Now Underway 31
Slide 32: PF-04360365: Pfizer's Anti-Amyloid Monoclonal Antibody
PF-04360365: Pfizer’s Anti-Amyloid Monoclonal Antibody m266 (LY 2062430) Targets AA 16 24; IgG1 PF 04360365 Bapineuzimab Targets AA 33 40; IgG2'a Targets AA 1 5; IgG1 N Terminus C Terminus Sources: Cowen and Company Dec 17, 2007; Siemers et al, International Conference on Alzheimer s disease; Madrid
Slide 33: Preclinical Monoclonal Antibody Data at ICAD Validates Proof of Concept
Preclinical Monoclonal Antibody Data at ICAD Validates Proof of Concept 33
Slide 34: Phase 1 Monoclonal Antibody Study Now Underway
Phase 1 Monoclonal Antibody Study Now Underway 34
Slide 35: Pfizer Driving Science of PDE9 Inhibition
Pfizer Driving Science of PDE9 Inhibition Pfizer is the only company with a PDE-9 compound in the clinic; currently in Phase 1 35
Slide 36: AD Summary
AD Summary ` AD is an area with high unmet need resulting in a significant commercial opportunity A leading neuro-psychiatric cause of disability World population of 20 million+ patients growing, with approximately only one quarter currently being treated ` Pfizer is in a strong position to acce
Slide 37: Investing to Win in Schizophrenia and Bipolar Disorder
Investing to Win in Schizophrenia and Bipolar Disorder 37
Slide 38: Schizophrenia Symptom Domains
Schizophrenia Symptom Domains Positive Affective Delusions Dysphoria Hallucinations Depression Unusual behavior Social and Occupational Dysfunction Negative Cognitive Flat affect Attention Social withdrawal Memory Emotional withdrawal Executive function Decision making Black DW et al. Introductory T
Slide 39: Severe Mental Illness a Leading Cause of Global Disability with Significant Costs
Severe Mental Illness a Leading Cause of Global Disability with Significant Costs Schizophrenia – U.S. Bipolar Disorder – U.S. ` Total costs est. $63B (2002)2 ` Total economic costs est. $45B Medical care utilization: $22.7B (1991)3 Indirect costs due to loss Medical care utilization: $7B of p
Slide 40: Management of Psychoses has Evolved; Significant Unmet Need Remains
Management of Psychoses has Evolved; Significant Unmet Need Remains 1990 – <1950 >1960 1990 – 2007 2008-2017 2007 Sanitariums Conventional Atypical Antipsychotics New MOAs Antipsychotics Surpass conventionals Highly Valued ` Prototype antipsychotic ` Clozapine 1st atypical ` Atypicals LOEs chlorprom
Slide 41: Pfizer's Symptom Focused Strategy Critical for Success
Pfizer’s Symptom Focused Strategy Critical for Success Schizophrenia Bipolar Disorder Treatment Acute Adjunctive Adjunctive Bipolar Maintenance Resistant Mania Mania BP Depression Depression Gold Gold Standard Standard Mood Mood Stabilizer Stabilizer Monotherapy Monotherapy Treat Treat acute acute m
Slide 42: Schizophrenia Points of Intervention
Schizophrenia Points of Intervention 5-HT2C agonists D2 antagonists increase striatal increase striatal activity activity by inhibiting by blocking dopamine dopamine cell firing (DA) inhibition Group II Glycine metabotropic Transporters glutamate (GlyT) receptor increase synaptic agonists levels of
Slide 43: Dopamine (D2) Partial Agonist – Phase 2 Study Underway
Dopamine (D2) Partial Agonist – Phase 2 Study Underway 43
Slide 44: Glycine Transport Inhibitor Targets Cognition in Schizophrenia
Glycine Transport Inhibitor Targets Cognition in Schizophrenia LTP 44
Slide 45: mGluR2/3 Agonist Now in Phase 1
mGluR2/3 Agonist Now in Phase 1 Metabotropic Glutamate Receptors in the Synapse mGluR2/3 Receptors are Presynaptic and Directly Modulate Glutamate Release SnyderEM, Murphy MR. Schizophrenia Therapy: beyond atypical antipsychotics. Nat Rev Drug Discov 2008;7:6:471-1. 45
Slide 46: Schizophrenia & Bipolar Disorder Summary
Schizophrenia & Bipolar Disorder Summary ` Like Alzheimer’s, Schizophrenia and Bipolar disorder remain areas of high unmet medical need Schizophrenia is a leading cause of disability worldwide ` Pfizer is strongly positioned with a rich portfolio of early stage compounds that target novel as well
Slide 47: Recap & Future Outlook
Recap & Future Outlook Steve Romano, MD Vice President, Global Medical 47
Slide 48: Pfizer in Neuroscience – Key Takeaways
Pfizer in Neuroscience – Key Takeaways 5 Maximize value of marketed products 5 Aricept, Geodon, Lyrica, Chantix 5 27 assets in Clinical Development 5 Clinical Portfolio has almost doubled over the past 2 years 5 Number of patient studies has also doubled over the past 2 years 5 Keen focus on areas o
Slide 49: Q&A
Q&A 49